| Autor: |
Yang Liu, Daniel Valentin, Robert Jordan, Melissa H. Bloodworth, Roderick S. Tang, Shannon I. Phan, Christopher C. Stobart, Jack Greenhouse, Aditya Garg, Xing Cheng, Tatyana Orekov, Swagata Kar, Laurent Pessaint, Hanne Leth Andersen, Mariana F. Tioni, R. Stokes Peebles, Pei Yong Shi, Martin L. Moore, Danlu Wu, Angie Silva Pena, Xuping Xie |
| Rok vydání: |
2021 |
| Předmět: |
|
| Popis: |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of the COVID-19 global pandemic. Vaccines are needed to control the disease and bring an end to the pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its trimeric surface glycoprotein, spike, for entry into host cells. Here we describe the COVID-19 vaccine candidate MV-014-212, a live attenuated, recombinant human respiratory syncytial virus (RSV) expressing a chimeric SARS-CoV-2 spike as the only viral envelope protein. MV-014-212 was attenuated and immunogenic in African green monkeys (AGMs). One mucosal administration of MV-014-212 in AGMs protected against SARS-CoV-2 challenge, reducing the peak shedding of SARS-CoV-2 in the nose by more than 200-fold. MV-014-212 elicited mucosal immunity in the nose and neutralizing antibodies in serum that exhibited cross neutralization against two virus variants of concern. Intranasally delivered, live attenuated vaccines such as MV-014-212 entail low-cost manufacturing suitable for global deployment. MV-014-212 is currently in phase I clinical trials as a single-dose intranasal COVID-19 vaccine. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
